Good
Partially Aligned
Patient Risk:
Moderate
Summary
Most structural facts (brand/ingredient, dopamine agonist, PD indication, once-daily transdermal continuous delivery, patch application basics, and several adverse effects/risks) align with the provided label excerpts. Several safety statements are overstated or not supported with the label-excerpt specificity provided (notably “urgent medical help” triggers and dose/strength math for patch combinations). Missing material label warnings/precautions include sulfite sensitivity and impulse control/compulsive behaviors, and RLS-specific augmentation/rebound is omitted.
Category Scores
Accurate Statements
Neupro is the brand name for rotigotine.
Label describes NEUPRO (rotigotine) transdermal system; active ingredient rotigotine (e.g., Sections 11, 12).
Rotigotine is a dopamine agonist used in Parkinson’s disease.
Mechanism of action: rotigotine is a non-ergoline dopamine agonist (Section 12.1); Indication: NEUPRO indicated for Parkinson’s disease (Section 1.1).
Neupro patches are applied once per day.
Administration: “NEUPRO is applied once a day.” (Section 2.3).
Neupro patches deliver medication continuously through the skin.
Description: “provides continuous delivery… for 24 hours following application to intact skin.” (Section 11); label excerpt also supports 24-hour continuous delivery (Section 11).
Rotigotine can cause skin reactions at the patch site.
Application site reactions occurred at greater frequency (Section 5.10).
Neupro dosing is usually expressed in mg/24h (e.g., 1 mg/24h, 2 mg/24h, 4 mg/24h).
Strengths: “1 mg/24 hours… 8 mg/24 hours” (Section 3) and dosage described as mg/24 hours (Section 2.1, 2.2).
Hallucinations and confusion with rotigotine are more likely in older adults or at higher doses.
Label excerpt supports increased risk for hallucinations in advanced-stage PD (Section 5.3). Provided excerpts do not explicitly mention older adults or dose-dependent likelihood; see unsupported/omission sections for those aspects.
Unsupported Statements
Rotigotine is sometimes used for restless legs syndrome depending on country or labeling.
Label excerpt provided states RLS is an indication (Section 1.2) but does not support the “depending on country or labeling” conditionality.
Neupro patches are usually not taken as “immediate” doses like pills.
No label excerpt provided addresses comparison to “immediate” pill dosing; only that it is a transdermal system with 24-hour continuous delivery (Section 11) and once-daily application (Section 2.3).
If patches are applied incorrectly (wrong number, wrong strength, or wrong schedule), side effects can be more likely.
The provided excerpts include application instructions but do not explicitly state that incorrect patch use increases side-effect likelihood.
Common side effects of rotigotine include nausea.
Nausea is listed under most likely overdose symptoms (Section 10.1), but the provided excerpts do not list nausea as a common adverse reaction in general.
Common side effects of rotigotine include dizziness and low blood pressure on standing.
Symptomatic hypotension and syncope are discussed (Sections 5.4 and 5.5), but the provided excerpts do not explicitly label dizziness and orthostatic/standing effects as “common side effects.”
Common side effects of rotigotine include sleepiness.
Falling asleep/somnolence is discussed (Section 5.2), but the excerpt does not explicitly state “common side effects.”
Common side effects of rotigotine include hallucinations and confusion.
Hallucinations/psychosis is discussed (Section 5.3) but the excerpt does not explicitly state “common side effects” or quantify likelihood; confusion is discussed in overdose symptoms (Section 10.1) and hyperpyrexia/confusion warning (Section 5.14) but not as a common side effect.
Hallucinations and confusion with rotigotine are more likely in older adults or at higher doses.
Label excerpt supports increased risk for hallucinations in advanced-stage PD (Section 5.3), but does not explicitly state older adults or a general “higher doses” relationship within the provided text.
Severe dizziness or fainting with rotigotine warrants urgent medical help.
The label excerpt mentions postural/orthostatic hypotension and syncope (Sections 5.4-5.5), but does not include an instruction to seek urgent medical help for these specific symptoms.
Chest pain with rotigotine warrants urgent medical help.
No chest pain-related guidance is present in the provided label excerpts.
Trouble breathing with rotigotine warrants urgent medical help.
No trouble-breathing guidance is present in the provided label excerpts (though sulfite sensitivity includes asthmatic episodes; see omissions for related missing safety detail).
Severe confusion with rotigotine warrants urgent medical help.
The label excerpt includes confusion as part of a neuroleptic malignant syndrome-like symptom complex (Section 5.14) and confusion in overdose symptoms (Section 10.1), but does not provide urgent-medical-help wording.
If “X3” means three patches, the total daily dose is the sum of the mg/24h from each patch strength.
The label excerpt states the prescribed dose may be achieved using single or multiple patches (Section 2.3), but does not provide a rule for interpreting an “X3” shorthand or summing mg/24h from “three patches” in the way claimed.
Contradictions
Important Omissions
NEUPRO contraindication for hypersensitivity to rotigotine or components of the transdermal system.
Importance:
Moderate
Sulfite sensitivity warning (may cause allergic-type reactions, including anaphylactic symptoms and life-threatening/less severe asthmatic episodes).
Importance:
Moderate
Impulse control/compulsive behaviors warning (e.g., gambling urges, sexual urges, spending/binge eating).
Importance:
Moderate
RLS-specific risks of augmentation and rebound (worsening RLS symptoms and earlier onset/end-of-dose effect).
Importance:
Moderate
Label-specific guidance on patch application site rotation and not applying to the same site more than once every 14 days (the response only broadly discussed correct vs incorrect application).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Several safety-relevant details were generalized or not supported (e.g., “urgent medical help” triggers; dose interpretation rule for patch combinations; describing nausea/confusion/hallucinations as “common”). Omitted label warnings (sulfite sensitivity, impulse control, and RLS augmentation/rebound) could reduce the completeness of safety communication.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Partially Aligned
Primary Issue
Overstated/unsupported claims about “common” side effects and urgent-medical-help triggers; incorrect or unsupported dose/patch shorthand interpretation; incomplete coverage of label warnings for sulfite sensitivity, impulse control, and RLS augmentation/rebound.
Suggested Improvement
Limit safety statements to label-supported descriptions (avoid “common” and urgent-medical-help wording unless explicitly present in the provided label text). Remove or qualify unsupported conditional statements (country-dependent use; patch shorthand math). Include key label warnings/precautions present in the excerpts, especially sulfite sensitivity, impulse control, and RLS augmentation/rebound.